Theragen Etex Co Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Theragen Etex Co Limited with three other
companies in this sector in South Korea:
Daehwa Pharmaceutical Company Limited
sales of 110.14 billion Korean Won [US$92.85 million]
of which 73%
was Medicine Mafufacture),
Reyon Pharmaceutical Co Ltd
(122.99 billion Korean Won [US$103.68 million]
of which 100%
was Medicament), and
Dae Han New Pharm Co., Ltd.
(119.53 billion Korean Won [US$100.76 million]
of which 85%
was Finished Goods).
During the year ended December of 2018, sales at
Theragen Etex Co Limited were 117.47 billion Korean Won (US$99.03 million).
increase of 9.2%
versus 2017, when the company's sales were 107.59 billion Korean Won.
This was the third consecutive year of growth at Theragen Etex Co Limited.
Sales of Pharmaceutical Business Segment saw an increase
16.4% in 2018, from
82.43 billion Korean Won to 95.95 billion Korean Won.
Not all segments of Theragen Etex Co Limited experienced an increase in sales in 2018:
sales of Healthcare and Genome Analysis Business fell 14.5% to 21.52 billion Korean Won.